Alnylam Pharmaceuticals, Inc. with ticker code (ALNY) now have 23 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 405 and 141 suggesting an average Analsyt target price of $246.47. Given that the stocks previous close was at $186.03 this indicates there is a potential upside of 32.5%. Also worth taking note is the 50 day moving average now sits at $193.64 and the 200 day MA is $205.92. The total market capitalization for the company now stands at 23.59B. The current share price for the company is: 188.73 USD
The potential market cap would be $31,256,151,194 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 10.01 and a -15.34% return on assets.
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.
